Bionano Genomics Announces 47% Increase in Payment Determination for OGM Use in Hematologic Malignancies.
ByAinvest
Wednesday, Dec 3, 2025 8:08 am ET1min read
BNGO--
Bionano Laboratories, a subsidiary of Bionano Genomics, announced a 47% increase in payment determination for the Category I CPT code 81195, which applies to optical genome mapping (OGM) in hematologic malignancies. The new payment rate is $1853.22, up from $1263.53, effective January 1, 2026. This increase is expected to make it easier to offer OGM-based LDTs for hematologic malignancies and raise awareness of the utility of OGM in the oncology and clinical genetic testing communities.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet